Why Isolated Thromboxane Synthase Blockade Fails
Pharmacology has long attempted to create an antiplatelet agent with maximum target specificity. One approach was the isolated inhibition of the enzyme thromboxane synthase. The rationale was to block exclusively thromboxane $A_2$ synthesis without affecting cyclooxygenase (COX) activity.
However, this approach proved ineffective in practice. The failure stems from biochemical cascade features. When the terminal enzyme is blocked, its immediate substrate—cyclic endoperoxides—accumulates massively. These endoperoxides exhibit similar pharmacodynamic activity: like thromboxane itself, they can directly stimulate thromboxane receptors on the platelet membrane. As a result of this substitution, the antiplatelet effect is completely neutralized.
Mechanism of Action of Indobufen
The drug indobufen (trade name — Ibustrin) represents a successful implementation of the combined inhibition concept. Its mechanism of action bypasses the problem of active substrate accumulation. Indobufen blocks two critical enzymes simultaneously:
- Thromboxane synthase (reduces thromboxane $A_2$ production).
- Cyclooxygenase (prevents excessive formation of cyclic endoperoxides).
The key difference between indobufen and classic acetylsalicylic acid (ASA) lies in the nature of enzyme interaction. While ASA inactivates COX permanently, indobufen causes reversible inhibition of cyclooxygenase.
The biochemical effect of the drug is a sharp decrease in thromboxane $A_2$ synthesis. Simultaneously, there is a relative increase in prostacyclin $I_2$ levels. As a result, the prostacyclin/thromboxane ratio shifts favorably, providing reliable protection against thrombosis.
Pharmacodynamics and Clinical Effects
The pharmacodynamics of indobufen are not limited to mere interference with eicosanoid synthesis. The drug exerts multifaceted effects on the hemostatic system:
- Effectively suppresses platelet adhesion to the damaged vascular wall.
- Inhibits the release reaction of proaggregatory factors from platelet granules.
- Suppresses platelet aggregation (clumping).
Beyond its effects on platelets, indobufen improves blood rheology. This is achieved by increasing erythrocyte deformability—red blood cells become more pliable and pass more easily through narrow capillaries of the microcirculation.
Interestingly, the drug possesses anti-inflammatory and analgesic activity, aligning it with the effects of ASA. However, indobufen's safety profile appears more favorable: clinical data show that the risk of dangerous bleeding during its use is significantly lower than with acetylsalicylic acid therapy.
Alternative Pathway: Receptor Blockade
An alternative and highly modern approach to suppressing thromboxane activity is the direct blockade of its receptors. A prominent representative of this group is terutroban (Terutroban, trade name — Triplion).
Its mechanism of action is fundamentally different: terutroban acts as a reversible thromboxane $A_2$ receptor antagonist. It does not interfere with enzymes; instead, it simply blocks receptors on the platelet surface. This prevents platelet activation caused not only by thromboxane itself but also by any other eicosanoids, including cyclic endoperoxides. In modern pharmacology, terutroban is considered the most promising agent in this antiplatelet drug group.